Reportlinker Adds Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights From a US Oncologists' Survey
NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights from a US Oncologists' Survey
Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.
This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.
Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists' decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor's product fits
• Design messages to advance brand performance
Table of Contents
Executive Summary5
Chapter 1: Introduction6
Table 1. Treatment Options in Advanced Prostate Cancer7
Chapter 2: Respondent Demographics8
Table 2.1 Eligibility Criteria for Survey Participation8
Figure 2.1 Gender of Survey Respondents8
Figure 2.2 Years Since Medical School Graduation9
Figure 2.3 Practice Settings9
Figure 2.4 Practices in NCI Cancer Centers10
Figure 2.5 Geographic Settings10
Figure 2.6 Survey Respondents by States11
Figure 2.7 Number of Physicians in Practice Groups12
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen12
Chapter 3: Treatment of a patient with increased PSA and adenocarcinoma13
Figure 3.1 Next step in a patient with increased PSA and adenocarcinoma13
Figure 3.2 Tests to be performed at this time with the patient14
Figure 3.3 Confidence in treating to optimal outcome15
Figure 3.4 Treatment decision with disease progression16
Figure 3.5 Treatment decision with disease progression18
Figure 3.6 Factors that influenced treatment20
Chapter 4: Summary22
Appendix A: Survey Instrument23
Companies mentioned
Novartis, Astra Zeneca, Merck, Ferring, Abbott Laboratories, TEVA, Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Pfizer, Sanofi-aventis, Centocor/Ortho Biotech, EMD Serono, Dendreon, Celegene, Watson, Amgen
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article